TIAA CREF Investment Management LLC Increases Stake in Codexis, Inc. (CDXS)
TIAA CREF Investment Management LLC lifted its holdings in Codexis, Inc. (NASDAQ:CDXS) by 7.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 109,557 shares of the biotechnology company’s stock after purchasing an additional 7,263 shares during the quarter. TIAA CREF Investment Management LLC owned 0.23% of Codexis worth $597,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in CDXS. Bank of New York Mellon Corp lifted its position in shares of Codexis by 10.4% in the first quarter. Bank of New York Mellon Corp now owns 136,053 shares of the biotechnology company’s stock worth $653,000 after purchasing an additional 12,841 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Codexis by 4.2% in the first quarter. Geode Capital Management LLC now owns 226,644 shares of the biotechnology company’s stock worth $1,087,000 after purchasing an additional 9,191 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Codexis by 2.9% in the first quarter. Bank of America Corp DE now owns 25,477 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 717 shares in the last quarter. Prescott Group Capital Management L.L.C. lifted its position in shares of Codexis by 607.8% in the second quarter. Prescott Group Capital Management L.L.C. now owns 2,040,324 shares of the biotechnology company’s stock worth $11,120,000 after purchasing an additional 1,752,049 shares in the last quarter. Finally, Perkins Capital Management Inc. bought a new stake in shares of Codexis in the second quarter worth $164,000. 63.67% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently commented on CDXS shares. Zacks Investment Research raised shares of Codexis from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Jefferies Group LLC restated a “buy” rating and set a $9.00 target price (up from $8.00) on shares of Codexis in a report on Monday, October 2nd. ValuEngine upgraded shares of Codexis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. HC Wainwright boosted their target price on shares of Codexis from $8.00 to $8.50 and gave the stock a “buy” rating in a report on Friday, October 13th. Finally, BidaskClub upgraded shares of Codexis from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $7.50.
COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/17/tiaa-cref-investment-management-llc-increases-stake-in-codexis-inc-cdxs.html.
Codexis, Inc. (NASDAQ:CDXS) opened at $5.90 on Friday. Codexis, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $7.95.
In related news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of the business’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $5.78, for a total transaction of $6,126,800.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 9.80% of the stock is currently owned by insiders.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Stock Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related stocks with our FREE daily email newsletter.